Chemotherapy for advanced non-small cell lung cancer: Past, present, and future

Keyphrases

• Chemotherapy 100%
• Cisplatin 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Past-present 100%
• Futures Past 100%
• Non-small Cell Lung Cancer (NSCLC) 75%
• Metastatic Non-small Cell Lung Cancer 75%
• Paclitaxel 50%
• Novel Agents 50%
• Vinorelbine 50%
• Monoclonal Antibody 25%
• Molecular Biology 25%
• Meta-analysis 25%
• Survivors 25%
• Gene Therapy 25%
• 1-year Survival 25%
• Randomized Clinical Trial 25%
• Response Rate 25%
• Therapeutic Action 25%
• Carboplatin 25%
• Multi-agent Approach 25%
• Nihilism 25%
• Ontology 25%
• Docetaxel 25%
• Antisense 25%
• Best Supportive Care 25%
• Randomized Phase III Trial 25%
• Irinotecan 25%
• Combination Regimen 25%
• New Agents 25%
• Mechanistic Approach 25%
• Etoposide-cisplatin 25%
• Gemcitabine 25%
• Cisplatin-based Chemotherapy 25%
• Cellular Biology 25%
• New Drug Development 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Chemotherapy 100%
• Cisplatin 85%
• Paclitaxel 28%
• Vinorelbine 28%
• Drug Development 14%
• Disease 14%
• Clinical Study 14%
• Survival Rate 14%
• Carboplatin 14%
• Lung Cancer 14%
• Gemcitabine 14%
• Docetaxel 14%
• Etoposide 14%
• Monoclonal Antibody 14%
• Irinotecan 14%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Cisplatin 85%
• Hope 28%
• Paclitaxel 28%
• Vinorelbine 28%
• Disease 14%
• Meta-Analysis 14%
• Supportive Care 14%
• Gene Therapy 14%
• Antisense 14%
• Survival Rate 14%
• Clinical Study 14%
• Lung Cancer 14%
• Carboplatin 14%
• Gemcitabine 14%
• Etoposide 14%
• Chemotherapy 14%
• Docetaxel 14%
• Irinotecan 14%
• Monoclonal Antibody Therapy 14%